지질 나노입자 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)

Lipid Nanoparticle Market Summary

Overview:

• The global lipid nanoparticle market was valued at USD 1.10 billion in 2025 and is projected to reach USD 3.30 billion by 2034.
• The market is expected to expand at a CAGR of 13.0% during the forecast period 2026-2034, supported by the validation of lipid nanoparticles as the leading delivery system for messenger RNA, the expansion of RNA and nucleic acid therapeutics beyond vaccines, the advance of ionizable lipids and formulation technology, and the growth of specialized manufacturing capacity.
• By composition, the ionizable lipids segment dominated the lipid nanoparticle market with a 38% share in 2025.
• By payload, the messenger RNA segment dominated the lipid nanoparticle market with a 48% share in 2025.
• By application, the infectious disease and vaccines segment dominated the lipid nanoparticle market with a 44% share in 2025.
• By end-user, the pharmaceutical and biotechnology companies segment dominated the lipid nanoparticle market with a 58% share in 2025.
• North America accounted for the largest share of the lipid nanoparticle market at 44% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Lipid nanoparticles are lipid-based delivery systems that encapsulate and deliver nucleic acid and other therapeutic payloads into cells, protecting the payload from degradation and enabling its cellular uptake and intracellular release. The scope encompasses the lipid components that constitute the nanoparticle, namely the ionizable lipid that binds and releases the nucleic acid, the phospholipid or helper lipid, the cholesterol that provides structure, and the polyethylene glycol lipid that stabilizes the particle, together with the formulation technologies, reagents, and services that produce lipid nanoparticles. Lipid nanoparticles are the delivery system of the messenger RNA vaccines against COVID-19 and of the first approved small interfering RNA therapeutic, and leading participants include the developers of proprietary ionizable lipids such as Acuitas Therapeutics and Genevant Sciences, the suppliers of lipid components such as Avanti Polar Lipids, Evonik, and Merck, and the providers of formulation technology and manufacturing such as Cytiva through Precision NanoSystems and the specialized contract manufacturers. The contemporary market is defined by the validation of lipid nanoparticles for messenger RNA, the expansion of RNA and nucleic acid therapeutics, and the advance of ionizable lipids and manufacturing.

Lipid Nanoparticle Market Key Growth Drivers

• Validation of lipid nanoparticles as the leading delivery system for messenger RNA, demonstrated by the messenger RNA vaccines against COVID-19.
• Expansion of RNA and nucleic acid therapeutics beyond vaccines into oncology, rare and genetic diseases, and gene editing.
• Advance of ionizable lipids and formulation technology that improve encapsulation, potency, and targeting.
• Growth of small interfering RNA therapeutics, following the first approved lipid nanoparticle small interfering RNA product.
• Growth of specialized lipid nanoparticle manufacturing capacity and contract manufacturing.
• Deep and growing pipeline of lipid nanoparticle-enabled drugs across modalities and indications.
• Investment in domestic manufacturing capacity and supply chain security for lipids and lipid nanoparticles.

Key Companies in Lipid Nanoparticle Market

The leading participants in the lipid nanoparticle market include the following:

• Merck KGaA
• Evonik Industries AG
• Cytiva (Danaher Corporation)
• CordenPharma International
• Croda International Plc
• Acuitas Therapeutics Inc.
• Genevant Sciences Corporation
• Thermo Fisher Scientific Inc.
• Lonza Group AG
• NOF Corporation

Factors Contributing to the Growth of the Lipid Nanoparticle Market

Market Drivers

Validation of Lipid Nanoparticles as the Leading Delivery System for Messenger RNA

The foundational driver of the lipid nanoparticle market is the validation of lipid nanoparticles as the leading delivery system for messenger RNA, demonstrated at global scale by the messenger RNA vaccines against COVID-19. Messenger RNA is fragile and cannot enter cells on its own, and lipid nanoparticles protect the messenger RNA from degradation and ensure that it is taken up into cells where it is translated into the encoded protein, making the lipid nanoparticle the enabling delivery system of messenger RNA medicine. The messenger RNA vaccines against COVID-19, delivered in lipid nanoparticles, were administered in billions of doses and demonstrated the safety, efficacy, and scalability of lipid nanoparticle delivery, transforming lipid nanoparticles from a specialized delivery option into a core enabling platform for vaccines and nucleic acid therapeutics. The clinical and commercial validation of lipid nanoparticles for messenger RNA, at unprecedented scale, established the lipid nanoparticle as the delivery system of choice for messenger RNA and catalyzed the expansion of messenger RNA and nucleic acid medicine. The demonstrated performance and scalability of lipid nanoparticle delivery, and the transition of messenger RNA into a mainstream therapeutic modality, drive the demand for lipid nanoparticles. As messenger RNA medicine expands on the validated foundation of lipid nanoparticle delivery, demand for lipid nanoparticles grows. The validation of lipid nanoparticles as the leading delivery system for messenger RNA anchors the growth of the market across the forecast period.

Expansion of RNA and Nucleic Acid Therapeutics Beyond Vaccines

The expansion of RNA and nucleic acid therapeutics beyond vaccines into oncology, rare and genetic diseases, and gene editing is a defining driver that broadens and deepens the demand for lipid nanoparticles. The validation of messenger RNA and lipid nanoparticles in vaccines has catalyzed the expansion of RNA and nucleic acid medicine into a broad range of applications, and messenger RNA applications have broadened beyond vaccines into oncology, rare diseases, protein replacement, and gene editing, creating a surge of clinical programs that require lipid nanoparticle delivery. Lipid nanoparticles deliver messenger RNA, small interfering RNA, self-amplifying RNA, plasmid DNA, and gene editing systems for the treatment of infectious diseases, cancer, rare and genetic diseases, cardiovascular and metabolic diseases, and other conditions, and the breadth of payloads and indications enlarges the demand for lipid nanoparticles. The expansion of RNA and nucleic acid therapeutics into new modalities and indications, the growth of the clinical pipeline, and the versatility of lipid nanoparticles across payloads drive the demand for lipid nanoparticle delivery. As RNA and nucleic acid therapeutics expand beyond vaccines into a broad range of modalities and indications, the demand for the lipid nanoparticle delivery they require grows and diversifies. The expansion of RNA and nucleic acid therapeutics beyond vaccines sustains demand for lipid nanoparticles across the forecast period.

Market Restraints

The lipid nanoparticle market faces several interrelated restraints that temper its growth. The foremost is the complexity and cost of formulation and manufacturing, since the development and manufacture of lipid nanoparticles require specialized lipids, formulation technology, good manufacturing practice facilities, analytical testing, and expertise, and the requirement for specialized equipment, facilities, and expertise increases the cost and complexity of production, particularly for smaller companies.

The intellectual property surrounding ionizable lipids and lipid nanoparticle technology is complex and concentrated, since the key ionizable lipids and delivery technologies are protected by patents held by a limited number of developers, and the licensing and freedom-to-operate requirements tied to this intellectual property add cost, complexity, and constraint. The challenge of delivery beyond the liver persists, since lipid nanoparticles naturally accumulate in the liver, and the targeting of other tissues and organs requires the advance of ionizable lipids and targeting technology that is still developing. The scalability, reproducibility, and analytical characterization of lipid nanoparticles are technically challenging, since the manufacture of consistent, well-characterized lipid nanoparticles at scale requires advanced formulation and analytical technology.

The cold chain and stability requirements of some lipid nanoparticle products add complexity and cost to storage and distribution. The regulatory requirements for the characterization, quality, and safety of lipid nanoparticles and their components add development burden. The concentration of lipid supply and the dependence on specialized suppliers create supply chain risk, and the tolerability and immunogenicity of some lipid components require management. The dependence of the market on the success and progression of the RNA and nucleic acid pipeline exposes it to the risks of drug development. Together, these factors moderate the pace and scope of growth and require participants to advance lipid design, formulation, manufacturing, and intellectual property to sustain growth.

Lipid Nanoparticle Market Segment Analysis

The global lipid nanoparticle market is segmented by composition (ionizable lipids, phospholipids and helper lipids, cholesterol, polyethylene glycol lipids), by payload (messenger rna, small interfering rna, dna and plasmid dna, and others), by application (infectious disease and vaccines, oncology, rare and genetic diseases, and others), and by end-users (pharmaceutical and biotechnology companies, academic and research institutes, and contract research and manufacturing organizations) by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Composition

Dominant Subsegment: Ionizable Lipids.

The ionizable lipids category is expected to dominate the market. The ionizable lipids segment accounted for a 38% share of the lipid nanoparticle market in 2025. Ionizable lipids, which bind the nucleic acid during formulation and release it inside the cell, are the leading composition category because they are the key and highest-value component of the lipid nanoparticle, determining the encapsulation, potency, tolerability, and biodistribution of the particle. The dominance of the segment reflects the central role of the ionizable lipid in lipid nanoparticle performance, the concentration of intellectual property and value in the ionizable lipid, and the intensive development of novel ionizable lipids. Ionizable lipids shift charge with pH to bind nucleic acids during formulation and to enable release inside the cell, and their design determines the performance of the lipid nanoparticle, making them the object of intensive development and the highest-value component. Developers have designed large libraries of proprietary ionizable lipids, and the ionizable lipid is the component most closely tied to the performance and the intellectual property of the lipid nanoparticle. The central role, the value, and the intensive development of ionizable lipids drive the segment. While phospholipids, cholesterol, and polyethylene glycol lipids are essential components of the lipid nanoparticle, the central role, value, and development of the ionizable lipid sustain the leadership of the ionizable lipids segment across the forecast period.

By Payload

Dominant Subsegment: Messenger RNA.

The messenger RNA category is expected to dominate the market. The messenger RNA segment accounted for a 48% share of the lipid nanoparticle market in 2025. Messenger RNA, which encodes proteins for vaccines and therapeutics, is the leading payload because it is the payload that validated lipid nanoparticle delivery at scale in the COVID-19 vaccines and drives the largest and fastest-expanding application of lipid nanoparticles. The dominance of the segment reflects the validation of lipid nanoparticle delivery of messenger RNA at global scale, the breadth of messenger RNA applications, and the central role of lipid nanoparticles as the delivery system of messenger RNA medicine. Lipid nanoparticles are the enabling delivery system of messenger RNA, protecting it and delivering it into cells, and messenger RNA vaccines and therapeutics represent the largest application of lipid nanoparticles, spanning infectious diseases, oncology, rare diseases, and protein replacement. The validation of messenger RNA delivery, the breadth of messenger RNA applications, and the central role of lipid nanoparticles in messenger RNA medicine drive the segment. While small interfering RNA, self-amplifying RNA, DNA, and gene editing payloads are important and growing, with small interfering RNA growing rapidly, the scale, validation, and breadth of messenger RNA sustain the leadership of the messenger RNA segment across the forecast period.

Lipid Nanoparticle Market Region Analysis

Dominant Region: North America

North America accounted for a 44% share of the global lipid nanoparticle market in 2025, representing the highest regional market share globally. The leadership of the region reflects the concentration of messenger RNA and nucleic acid developers, the presence of the leading ionizable lipid and delivery technology companies, the strength of research and investment, and the investment in domestic lipid manufacturing. The United States is the largest national market, supported by the concentration of the messenger RNA and nucleic acid pharmaceutical and biotechnology companies, the presence of the leading ionizable lipid, lipid component, and formulation technology companies, the strength of research funding and investment in RNA and nucleic acid medicine, and the investment in domestic lipid manufacturing capacity and supply chain security. The concentration of biotechnology hubs, the presence of developers and suppliers, the strength of investment, and the establishment of domestic lipid manufacturing facilities supported by government programs drive the market, and the leading companies operate extensively in the region. The concentration of developers and suppliers, the strength of research and investment, and the investment in domestic manufacturing reinforce the leadership of the region. The combination of developer concentration, supplier presence, investment strength, and domestic manufacturing sustains the position of North America as the largest regional market across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region combines the rapid growth of its biotechnology and pharmaceutical industry, the expansion of messenger RNA and nucleic acid research and manufacturing, the growth of contract manufacturing, and the increase in investment, which drives the fast growth of the market. China, Japan, South Korea, and India are the principal national markets, supported by the rapid growth of messenger RNA and nucleic acid research and development, the expansion of lipid nanoparticle formulation and manufacturing capacity, the growth of contract manufacturing and lipid supply, and the increase in investment and government support for RNA medicine. The growth of the biotechnology industry, the expansion of RNA and nucleic acid development and manufacturing, and the growth of lipid nanoparticle capacity enlarge the demand for lipid nanoparticles. As the biotechnology and pharmaceutical industry grows, as RNA and nucleic acid development expands, and as lipid nanoparticle manufacturing capacity grows, the region increases its demand and provision from a growing base, and the scale of the industry and the expansion of manufacturing create substantial long-term demand. The combination of industry growth, research and manufacturing expansion, and investment positions Asia-Pacific as the fastest-growing regional market, and it attracts investment and the expansion of global and regional companies.

Regional Commentary

North America

North America leads the market, supported by the concentration of messenger RNA and nucleic acid developers, the presence of the leading ionizable lipid and delivery technology companies, the strength of research and investment, and the investment in domestic lipid manufacturing. The United States dominates the region through its concentration of developers and suppliers, the strength of investment, and the establishment of domestic lipid manufacturing facilities. The growth of RNA and nucleic acid medicine sustains demand.

Europe

Europe is a substantial market shaped by a strong biotechnology and pharmaceutical industry, the presence of lipid suppliers and contract manufacturers including Evonik, Merck, CordenPharma, and Croda, and the growth of RNA and nucleic acid development. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, supported by the biotechnology and pharmaceutical industry, lipid manufacturing capacity, and the growth of messenger RNA and nucleic acid medicine. Demand is sustained by RNA and nucleic acid development and the presence of lipid suppliers and manufacturers.

Asia-Pacific

Asia-Pacific is the fastest-growing region, driven by the rapid growth of messenger RNA and nucleic acid research, the expansion of formulation and manufacturing capacity, and the growth of contract manufacturing across China, Japan, South Korea, and India. Industry growth, research and manufacturing expansion, and investment sustain rapid growth, and the region attracts investment and the expansion of global and regional companies.

Rest of World

The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as biotechnology research and vaccine and therapeutic manufacturing grow. Growth is supported by the growth of RNA and vaccine development, the expansion of manufacturing, and the increasing use of lipid nanoparticle delivery, though research and manufacturing capacity vary by market. Companies pursue these markets through lipid supply, formulation, and manufacturing suited to growing RNA and vaccine development.

Lipid Nanoparticle Market Competitive Landscape

The global lipid nanoparticle market is classified as Moderately Consolidated. A group of ionizable lipid, lipid component, and formulation and manufacturing companies holds a substantial share of the market through proprietary lipids, components, and capabilities, while delivery technology and contract manufacturing specialists compete on technology, quality, and capacity. Competition centers on the performance and intellectual property of ionizable lipids, the quality and supply of lipid components, the formulation technology and manufacturing capacity, the breadth from discovery through commercial supply, and the good manufacturing practice quality and supply chain security; technology advances, capacity investment, and partnerships intensify the contest. The competitive landscape is evaluated across the following dimensions:

• Market concentration: Moderately consolidated, with a group of ionizable lipid, lipid component, and formulation and manufacturing companies holding a substantial share, alongside delivery technology and contract manufacturing specialists.
• Leading players: Merck, Evonik, Croda through Avanti Polar Lipids, and CordenPharma lead in lipid components and manufacturing; Cytiva through Precision NanoSystems leads in formulation technology; Acuitas Therapeutics and Genevant Sciences lead in proprietary ionizable lipids and delivery technology, and Thermo Fisher, Lonza, and NOF contest lipids, formulation, and manufacturing.
• Geographic reach: The leading lipid and manufacturing companies operate global supply and manufacturing, with concentration in North America and Europe and expanding capacity in Asia-Pacific.
• Product portfolio strength: Competitive advantage rests on the performance and intellectual property of ionizable lipids, the quality and supply of lipid components, the formulation technology, and the breadth from discovery through good manufacturing practice commercial supply.
• Pipeline strength: Development is concentrated in next-generation ionizable lipids, targeting beyond the liver, formulation and manufacturing technology, and good manufacturing practice capacity.
• Strategic partnerships: Collaboration spans partnerships between lipid, technology, and manufacturing companies and RNA developers, licensing of ionizable lipids and delivery technology, and alliances that combine lipids, formulation, and manufacturing.
• M&A activity: Consolidation has shaped the field, with life science and manufacturing companies acquiring lipid, delivery technology, and formulation capabilities, exemplified by the acquisition of Precision NanoSystems by Cytiva, alongside continued partnership and investment.
• Innovation focus: Innovation is shifting toward next-generation ionizable lipids, targeting beyond the liver, advanced and continuous manufacturing, and good manufacturing practice quality and supply chain security.
• Regulatory standing: Good manufacturing practice quality of lipids and lipid nanoparticles, the characterization and quality of components and formulations, and the security and reliability of supply are decisive competitive credentials and a principal axis of competition among the leaders.

Lipid Nanoparticle Market Recent Developmental Activities

In 2018, the first lipid nanoparticle small interfering RNA therapeutic was approved, delivering small interfering RNA in a lipid nanoparticle and validating lipid nanoparticles for small interfering RNA. Strategic significance: the approval established lipid nanoparticles as a clinical delivery system and preceded their validation at scale in messenger RNA vaccines.

In February 2024, CordenPharma International introduced lipid nanoparticle starter kits designed to support messenger RNA therapeutic development by simplifying lipid screening and formulation optimization. Strategic significance: the launch lowered the barrier to lipid nanoparticle development and reinforced the position of a leading lipid and manufacturing company.

Lipid Nanoparticle Market Segmentation

Lipid Nanoparticle Market Assessment by Composition

• Ionizable Lipids
• Phospholipids and Helper Lipids
• Cholesterol
• Polyethylene Glycol Lipids

Lipid Nanoparticle Market Assessment by Payload

• Messenger RNA
• Small Interfering RNA
• DNA and Plasmid DNA
• Others

Lipid Nanoparticle Market Assessment by Application

• Infectious Disease and Vaccines
• Oncology
• Rare and Genetic Diseases
• Others

Lipid Nanoparticle Market Assessment by End-User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research and Manufacturing Organizations

Lipid Nanoparticle Market Assessment by Geography

• North America
• United States Lipid Nanoparticle Market Size in USD million (2023-2034)
• Canada Lipid Nanoparticle Market Size in USD million (2023-2034)
• Mexico Lipid Nanoparticle Market Size in USD million (2023-2034)
• Europe
• Germany Lipid Nanoparticle Market Size in USD million (2023-2034)
• United Kingdom Lipid Nanoparticle Market Size in USD million (2023-2034)
• France Lipid Nanoparticle Market Size in USD million (2023-2034)
• Italy Lipid Nanoparticle Market Size in USD million (2023-2034)
• Spain Lipid Nanoparticle Market Size in USD million (2023-2034)
• Rest of Europe Lipid Nanoparticle Market Size in USD million (2023-2034)
• Asia-Pacific
• China Lipid Nanoparticle Market Size in USD million (2023-2034)
• Japan Lipid Nanoparticle Market Size in USD million (2023-2034)
• India Lipid Nanoparticle Market Size in USD million (2023-2034)
• Australia Lipid Nanoparticle Market Size in USD million (2023-2034)
• South Korea Lipid Nanoparticle Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Lipid Nanoparticle Market Size in USD million (2023-2034)
• Rest of the World
• Middle East Lipid Nanoparticle Market Size in USD million (2023-2034)
• Africa Lipid Nanoparticle Market Size in USD million (2023-2034)
• South America Lipid Nanoparticle Market Size in USD million (2023-2034)

Key Takeaways from the Lipid Nanoparticle Market Report Study

• Market size analysis for the current lipid nanoparticle market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key lipid, delivery technology, and manufacturing developments, partnerships, launches, and investments that happened over the last 3 years.
• Key companies dominating the global lipid nanoparticle market.
• Various opportunities available for competitors in the lipid nanoparticle market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current lipid nanoparticle market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for lipid nanoparticle market growth in the future?

Target audience who can benefit from this lipid nanoparticle market report study

• Lipid nanoparticle, lipid, delivery technology, and contract manufacturing providers
• Research organizations and consulting companies
• Lipid nanoparticle and RNA medicine-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Pharmaceutical, biotechnology, and research organizations dealing in RNA and nucleic acid medicine
• Various end-users who want to know more about the lipid nanoparticle market and the latest technological developments in the lipid nanoparticle market.

Frequently Asked Questions:

Q1. At what rate is the lipid nanoparticle market expected to grow?

The global lipid nanoparticle market is projected to grow at a compound annual growth rate of 13.0% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the lipid nanoparticle market?

The global lipid nanoparticle market was valued at USD 1.10 billion in 2025 and is projected to reach USD 3.30 billion by 2034.

Q3. Which region dominates the lipid nanoparticle market?

North America dominated the lipid nanoparticle market with a 44% share in 2025, driven by the concentration of messenger RNA and nucleic acid developers, the presence of the leading ionizable lipid and delivery technology companies, the strength of research and investment, and the investment in domestic lipid manufacturing. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by the rapid growth of messenger RNA and nucleic acid research and the expansion of manufacturing capacity across China, Japan, South Korea, and India.

Q4. What are the key factors driving growth in the lipid nanoparticle market?

The principal drivers are the validation of lipid nanoparticles as the leading delivery system for messenger RNA; the expansion of RNA and nucleic acid therapeutics beyond vaccines into oncology, rare diseases, and gene editing; the advance of ionizable lipids and formulation technology; the growth of small interfering RNA therapeutics; the growth of specialized manufacturing capacity; and the investment in domestic manufacturing and supply chain security.

Q5. Who are the major players in the lipid nanoparticle market?

The market is moderately consolidated and led by Merck KGaA, Evonik Industries AG, Cytiva through Precision NanoSystems, CordenPharma International, and Croda International Plc through Avanti Polar Lipids, alongside Acuitas Therapeutics Inc., Genevant Sciences Corporation, Thermo Fisher Scientific Inc., Lonza Group AG, and NOF Corporation. Additional participants, including Catalent, Inc., FUJIFILM, Ascendia Pharmaceuticals, and NanoVation Therapeutics, compete across ionizable lipids, lipid components, formulation technology, and manufacturing.

Table of Contents

1. Introduction

• 1.1. Scope of the Report
• 1.2. Market Segmentation
• 1.3. Market Overview at a Glance

2. Executive Summary of Lipid Nanoparticle Market

• 2.1. Key Highlights and Market Snapshot

3. Key Factors Impacting the Lipid Nanoparticle Market

• 3.1. Market Drivers
  • 3.1.1. Validation of Lipid Nanoparticles as the Leading Delivery System for Messenger RNA
  • 3.1.2. Expansion of RNA and Nucleic Acid Therapeutics Beyond Vaccines
  • 3.1.3. Advances in Ionizable Lipids and Formulation Technology
  • 3.1.4. Small Interfering RNA, Manufacturing Capacity, and Supply Chain Security
• 3.2. Market Restraints
  • 3.2.1. Complexity and Cost of Formulation and Manufacturing
  • 3.2.2. Intellectual Property and Delivery Beyond the Liver
  • 3.2.3. Scalability, Supply, and Pipeline Dependence
• 3.3. Market Opportunities
  • 3.3.1. Next-Generation Ionizable Lipids and Targeted Delivery
  • 3.3.2. Emerging Markets and Expanding Applications

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

• 5.1. The United States
• 5.2. Europe
• 5.3. Japan
• 5.4. China

6. Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Lipid Nanoparticle Market Assessment

• 7.1. By Composition
  • 7.1.1. Ionizable Lipids
  • 7.1.2. Phospholipids and Helper Lipids
  • 7.1.3. Cholesterol
  • 7.1.4. Polyethylene Glycol Lipids
• 7.2. By Payload
  • 7.2.1. Messenger RNA
  • 7.2.2. Small Interfering RNA
  • 7.2.3. DNA and Plasmid DNA
  • 7.2.4. Others
• 7.3. By Application
  • 7.3.1. Infectious Disease and Vaccines
  • 7.3.2. Oncology
  • 7.3.3. Rare and Genetic Diseases
  • 7.3.4. Others
• 7.4. By End-User
  • 7.4.1. Pharmaceutical and Biotechnology Companies
  • 7.4.2. Academic and Research Institutes
  • 7.4.3. Contract Research and Manufacturing Organizations
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.1.2. Canada Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.1.3. Mexico Lipid Nanoparticle Market Size in USD million (2023-2034)
  • 7.5.2. Europe
    • 7.5.2.1. Germany Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.2.2. United Kingdom Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.2.3. France Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.2.4. Italy Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.2.5. Spain Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.2.6. Rest of Europe Lipid Nanoparticle Market Size in USD million (2023-2034)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.3.2. Japan Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.3.3. India Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.3.4. Australia Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.3.5. South Korea Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.3.6. Rest of Asia-Pacific Lipid Nanoparticle Market Size in USD million (2023-2034)
  • 7.5.4. Rest of the World
    • 7.5.4.1. Middle East Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.4.2. Africa Lipid Nanoparticle Market Size in USD million (2023-2034)
    • 7.5.4.3. South America Lipid Nanoparticle Market Size in USD million (2023-2034)

8. Lipid Nanoparticle Market Competitive Landscape

• 8.1. Competitive Analysis
• 8.2. Company Share Analysis (Premium Offering)

9. Lipid Nanoparticle Market Startup Funding and Investment Trends

10. Company and Product Profiles

• 10.1. Merck KGaA
  • 10.1.1. Company Overview
  • 10.1.2. Company Snapshot
  • 10.1.3. Financial Overview
  • 10.1.4. Product Portfolio
  • 10.1.5. Strategic Initiatives / Entropy
• 10.2. Evonik Industries AG
  • 10.2.1. Company Overview
  • 10.2.2. Company Snapshot
  • 10.2.3. Financial Overview
  • 10.2.4. Product Portfolio
  • 10.2.5. Strategic Initiatives / Entropy
• 10.3. Cytiva (Danaher Corporation)
  • 10.3.1. Company Overview
  • 10.3.2. Company Snapshot
  • 10.3.3. Financial Overview
  • 10.3.4. Product Portfolio
  • 10.3.5. Strategic Initiatives / Entropy
• 10.4. CordenPharma International
  • 10.4.1. Company Overview
  • 10.4.2. Company Snapshot
  • 10.4.3. Financial Overview
  • 10.4.4. Product Portfolio
  • 10.4.5. Strategic Initiatives / Entropy
• 10.5. Croda International Plc
  • 10.5.1. Company Overview
  • 10.5.2. Company Snapshot
  • 10.5.3. Financial Overview
  • 10.5.4. Product Portfolio
  • 10.5.5. Strategic Initiatives / Entropy
• 10.6. Acuitas Therapeutics Inc.
  • 10.6.1. Company Overview
  • 10.6.2. Company Snapshot
  • 10.6.3. Financial Overview
  • 10.6.4. Product Portfolio
  • 10.6.5. Strategic Initiatives / Entropy
• 10.7. Genevant Sciences Corporation
  • 10.7.1. Company Overview
  • 10.7.2. Company Snapshot
  • 10.7.3. Financial Overview
  • 10.7.4. Product Portfolio
  • 10.7.5. Strategic Initiatives / Entropy
• 10.8. Thermo Fisher Scientific Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Company Snapshot
  • 10.8.3. Financial Overview
  • 10.8.4. Product Portfolio
  • 10.8.5. Strategic Initiatives / Entropy
• 10.9. Lonza Group AG
  • 10.9.1. Company Overview
  • 10.9.2. Company Snapshot
  • 10.9.3. Financial Overview
  • 10.9.4. Product Portfolio
  • 10.9.5. Strategic Initiatives / Entropy
• 10.10. NOF Corporation
  • 10.10.1. Company Overview
  • 10.10.2. Company Snapshot
  • 10.10.3. Financial Overview
  • 10.10.4. Product Portfolio
  • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us